tirzepatide 2.2mg compound hcpc code | C225H348N48O68 | CID 156588324 Use of the dual GIP/GLP-1

If pregnancy is recognized during treatment, the medication should be discontinued immediately and the healthcare provider contacted promptly

During dose escalation periods, when energy levels may be lower, prioritize strength training over cardio

How It Works (StepbyStep) Complete a health intake Meet virtually with a licensed obesity medication provider and a dietician Complete lab work, ordered at your providers discretion If approved, receive compounded tirzepatide by mail or pick-up brand-name prescriptions at your local pharmacy Ongoing support through the secure Mochi portal Geographic Availability Available in all 50 states Clinical Oversight and Safety Board-certified obesity medicine specialists Dose adjustments reviewed via follow-up and messaging Secure portal for clinical questions 24/7 support and care team messaging Treatments Offered Weekly GLP-1 injections: compounded tirzepatide

About 1 in 9 people on the top dose (11.3%) stopped because of side effects, compared with 4.9% on placebo

HbA1c Reduction: Superior Glycemic Control One of the most important clinical goals in managing type 2 diabetes is reducing hemoglobin A1c (HbA1c), a marker of average blood glucose over time